An Open-label Extension Study to Evaluate the Safety and Tolerability of Licarbazepine 750-2000 mg/d in the Treatment of Manic Episodes of Bipolar I Disorder
NCT ID: NCT00238485
Last Updated: 2017-03-28
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
251 participants
INTERVENTIONAL
2005-01-31
2007-07-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
An Open-label Extension Study to Evaluate the Safety and Tolerability of Licarbazepine in the Treatment of Manic Episodes of Bipolar I Disorder.
NCT00228059
Open Label Extension Study of Licarbazepine in the Treatment of Manic Episodes of Bipolar I Disorder
NCT00139594
Study of Licarbazepine in the Treatment of Manic Episodes of Bipolar Disorder
NCT00099229
Study of Licarbazepine in the Treatment of Manic Episodes of Bipolar Disorder
NCT00107939
Study of Licarbazepine in the Treatment of Manic Episodes of Bipolar Disorder
NCT00107926
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
SINGLE_GROUP
DIAGNOSTIC
NONE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Licarbazepine
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* successful completion of the study CLIC477D2302
* willingness and ability to comply with all study requirements
Exclusion Criteria
* failure to comply with the study CLIC477D2302 protocol
18 Years
70 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Novartis
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Novartis Customer Care information
Role: STUDY_CHAIR
862-778-8300
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CLIC477D2302E1
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.